Acesys Pharmatech | USA | Inquire | ||
---|---|---|---|---|
![]() |
+1 (800) 792-0471 / (908) 998-1240 | |||
![]() |
info@acesyspharma.com, | |||
Chemical manufacturer | ||||
Apexmol Technology Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (10) 8290-0393 | |||
![]() |
sales@apexmol.com | |||
Chemical manufacturer since 2012 | ||||
Bide Pharmatech Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 4006-147-117 | |||
![]() |
sales@bidepharmatech.com | |||
![]() |
QQ Chat | |||
Chemical manufacturer since 2007 | ||||
International Laboratory Limited | USA | Inquire | ||
---|---|---|---|---|
![]() |
+1 (650) 278-9963 | |||
![]() |
admin@intlab.org | |||
Chemical manufacturer since 2002 | ||||
OX CHEM | USA | Inquire | ||
---|---|---|---|---|
![]() |
+1 (626) 461-2812 | |||
![]() |
sales@ox-chem.com | |||
CRO since 2013 | ||||
Otava Ltd. | Ukraine | Inquire | ||
---|---|---|---|---|
![]() |
+380 (44) 522-2458 | |||
![]() |
order@otavachemicals.com | |||
Chemical manufacturer since 1997 | ||||
ZereneX Molecular Ltd. | UK | Inquire | ||
---|---|---|---|---|
![]() |
+44 (1204) 527-700 | |||
![]() |
sales@zerenex-molecular.com | |||
Chemical manufacturer | ||||
Zylexa Pharma Ltd. | UK | Inquire | ||
---|---|---|---|---|
![]() |
+44 (845) 299-6009/ | |||
![]() |
sales@zylexa-pharma.com,enquiries@zylexa-pharma.com | |||
Chemical manufacturer | ||||
Name | 6-Methyl-4-Chromanamine Hydrochloride (1:1) |
---|---|
Synonyms | (R)-6-methylchroman-4-amine hydrochloride; 6-methyl-3,4-dihydro-2H-chromen-4-ylamine hydrochloride; 6-METHYLCHROMAN-4-AMINE HYDROCHLORIDE |
Molecular Structure | ![]() |
Molecular Formula | C10H14ClNO |
Molecular Weight | 199.68 |
CAS Registry Number | 191608-11-4 |
SMILES | Cc1ccc2c(c1)C(CCO2)N.Cl |
InChI | 1S/C10H13NO.ClH/c1-7-2-3-10-8(6-7)9(11)4-5-12-10;/h2-3,6,9H,4-5,11H2,1H3;1H |
InChIKey | XDTASUXSWBNHHX-UHFFFAOYSA-N |
Refractive index | (Cal.) |
---|---|
SDS | Available |
---|---|
Market Analysis Reports |
List of Reports Available for 6-Methyl-4-Chromanamine Hydrochloride (1:1) |